{"id":"dapa-met-xr","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"5-15","effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":"2-5","effect":"Polyuria"},{"rate":"1-3","effect":"Volume depletion"}]},"_chembl":{"chemblId":"CHEMBL258896","moleculeType":"Small molecule","molecularWeight":"549.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, promoting glucose excretion in urine independent of insulin secretion. Metformin reduces hepatic glucose production and improves insulin sensitivity. The combination provides complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"DAPA/MET XR is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and metformin extended-release that lowers blood glucose by increasing urinary glucose excretion and reducing hepatic glucose production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:33.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02338193","phase":"PHASE3","title":"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women","status":"COMPLETED","sponsor":"Woman's","startDate":"2015-09-22","conditions":"Diabetes Prevention in Women After GDM Who Are at High-risk","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xigduo 5mg/1000 mg"],"phase":"phase_3","status":"active","brandName":"DAPA/MET XR","genericName":"DAPA/MET XR","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAPA/MET XR is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and metformin extended-release that lowers blood glucose by increasing urinary glucose excretion and reducing hepatic glucose production. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}